Hims Hers Health Inc is trading 4.1% up now at $32.75 as investors extend a sharp multi-day rally following bullish growth expectations in new weight-loss related categories.

  • The move builds on prior sessions’ double-digit gains after coverage highlighted the company’s peptide and GLP-1 opportunity.
  • Analysts estimate that peptide expansion could drive up to $19 billion in annual revenue by 2030, keeping retail interest and momentum elevated.
  • The stock continues to show strength despite a mixed broader market, fueled by its strategic focus on the high-growth weight-loss sector.